(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Row 1: J Crisalli, R Amin, C Kercsmar, N Simakajornboon
Row 2: K McDowell, H Sawnani, P Joseph, R VanDyke, L Young
Row 3: M Ednick, W Hardie, M Seid, J Clancy, D Grossoehme
A collaborative in research which includes the division of Pulmonary Medicine, Otolaryngology, Radiology and Aerospace Engineering was funded by the NIH (Contact PI: Raouf Amin). The research aims at understanding the mechanisms of obstructive sleep apnea in children with Down Syndrome. Simulation models will be developed to predict the outcomes of surgical intervention aiming at treating upper airway obstruction. It is anticipated that the knowledge gained will translate into novel treatment of sleep apnea.
Dr. Seid’s research focuses on using behavioral and social science to improve care and outcomes for children with chronic health conditions. He has been Principal Investigator of numerous federally-funded grants, including grants to measure quality of care for vulnerable children (R01 HS10317), to reduce barriers to care for vulnerable children with asthma (R40 MC 001214/08044), to determine predictors of health-related quality of life for children with juvenile idiopathic arthritis (R01 subcomponent of P60 AR047784-06A2, Glass PI) and to develop and test a cell-phone based adherence intervention for adolescents with asthma (R21HL089524) and Type 1 diabetes (R21DK085483). Dr. Seid is the Research Center Director of Cincinnati Children's AHRQ-funded Center for Education and Research in Therapeutics (CERT; U18HS016957, Lannon PI), focusing on using learning networks for comparative effectiveness and safety research. He is also Co-PI for a Transformative R01 (R01DK085719), “Open Source Science: Transforming Chronic Illness Care,” which aims to design, develop, and test a new system for chronic illness care based on collaboration among patients, providers, and researchers.
An active program of pulmonary outcomes research unites clinical and research faculty as well as clinical staff in advancing the science of improving outcomes for children with pulmonary disease. Research is supported by divisional funding, Cincinnati Children’s Place Outcomes Research Awards and the National Institutes of Health. Members of the Pulmonary Outcomes Research Lab presented at national and international meetings this year and have published peer-reviewed articles. Highlights from this research group include: demonstrating the effectiveness of a common cystic fibrosis treatment using the national CF Foundation database; determining the relationship between physician behaviors and patient adherence using video recordings; understanding how parents cope with the diagnosis of their child and the role that spirituality and religion play in family adherence to the medical regimen; documenting the impact of scoliosis surgery on lung function; and testing interventions using text messaging to improve adherence for adolescents with asthma. This research aims to increase the division’s capability for improvement and develop knowledge and interventions to improve outcomes.
John “JP” Clancy, MD, joined the Pediatric Pulmonary Division in January 2011. He served as the division chief of pediatric pulmonology at the University of Alabama at Birmingham prior to joining the Cincinnati Children’s faculty, and upon his arrival he has been appointed the Thomas Boat endowed chair and director of CF clinical and translational research. He oversees the CFF-Therapeutic Development Network Translational Research Center at Cincinnati Children’s, and his laboratory and clinical research program focuses on airway and epithelial biology, examining novel targets to treat cystic fibrosis. His area of expertise includes developing agents to restore function to disease-causing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which is the root cause of CF. He also focuses on developing preclinical model systems and patient biomarkers to bridge these findings from the lab to the bedside. Clancy has played international leadership roles in drug development, study design and execution and data analysis for new cystic fibrosis therapeutics, and recently served as the international lead investigator of two phase 2 studies of new CF treatments. His translational research laboratory brings basic research laboratory personnel and clinical research coordinators together, and provides an environment for the training of students, medical professionals and research scientists in translational research.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center